Court documents say Allergy and Asthma Associates Inc. (AAA) submitted improper billings to Medicare and Medicaid for Xolair, an expensive asthma treatment sold in single-use vials. In situations where a patient’s dose resulted in a leftover partial vial of Xolair, AAA administered the leftover amount to another patient and then billed Medicare and Medicaid for administering this amount as if it were the entire single-use vial. Read a news story from CBS 19 News and a Department of Justice press release.
SMP Resource Center products often contain links to copyrighted material. The SMP Resource Center is providing these links as a convenience and for informational purposes in our efforts to report and educate on Medicare fraud; they do not constitute a guarantee, endorsement, or approval by SMP of any of the information available on the external site. SMP bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. If you have any questions or concerns about the links provided, please contact the SMP Center at nliebau@smpresource.org.